Health ❯ Healthcare ❯ Medical Research ❯ Neurology

Alzheimer's Disease

New Blood Biomarkers Differentiate Alzheimer’s Risk by Disease Stage

Recent studies find plasma p‑tau217 best detects clinical Alzheimer’s while amyloid‑beta misfolding and combined marker panels identify risk years earlier, shaping screening and trial approaches.

3 ARTICLES

4w ago

34‑circRNA Blood Signature Outperforms pTau217 in Detecting and Predicting Alzheimer’s

5 ARTICLES

2mo ago

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

3 ARTICLES

2mo ago

Glucosamine Linked to Faster Dementia Progression and Higher Death Risk, Study Finds

7 ARTICLES

2mo ago

Glucosamine Linked to Faster Progression and Higher Death Rates in Alzheimer’s Patients

16 ARTICLES

2mo ago

Blood Tests and New PET Tracer Reveal Early Alzheimer’s Signals in Some Middle‑Aged Adults

3 ARTICLES

3mo ago

Common Blood Test Marker Linked to Higher Future Dementia Risk, Large Study Finds

21 ARTICLES

4mo ago

Major Review Says New Alzheimer’s Antibodies Offer No Meaningful Benefit

9 ARTICLES

4mo ago

Germany Rules No Added Benefit for New Alzheimer Antibodies After Major Review Finds Little Effect

5 ARTICLES

4mo ago

Blood Test Detects Alzheimer’s Risk Years Before PET Scans

3 ARTICLES

4mo ago

Dual Blood Markers Sharpen Alzheimer’s Diagnosis by Cutting False Positives

20 ARTICLES

5mo ago

Blood Test Using p‑Tau217 Predicts Dementia Risk in Women Up to 25 Years Before Symptoms

5 ARTICLES

5mo ago

Early Alzheimer’s Markers Identified in Peripheral Retina in Mouse Study

17 ARTICLES

5mo ago

Blood ‘Clock’ Predicts Alzheimer’s Symptom Onset Within 3–4 Years

11 ARTICLES

5mo ago

G-BA Finds No Added Benefit for Alzheimer’s Drug Leqembi in Germany

7 ARTICLES

6mo ago

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Alzheimer's Disease

New Blood Biomarkers Differentiate Alzheimer’s Risk by Disease Stage

Donanemab Slows Alzheimer's Decline, New AAIC Data Show

Blood p‑tau217 Test Predicts Elevated 5‑ and 10‑Year Alzheimer’s Risk

Blood Test p‑tau217 Predicts Alzheimer Risk but Not Ready for Routine Screening

Biogen's Tau Drug Cuts Brain Tau but Misses Dose‑Response Goal

34‑circRNA Blood Signature Outperforms pTau217 in Detecting and Predicting Alzheimer’s

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Glucosamine Linked to Faster Dementia Progression and Higher Death Risk, Study Finds

Glucosamine Linked to Faster Progression and Higher Death Rates in Alzheimer’s Patients

Blood Tests and New PET Tracer Reveal Early Alzheimer’s Signals in Some Middle‑Aged Adults

Never miss stories about

Alzheimer's Disease

Common Blood Test Marker Linked to Higher Future Dementia Risk, Large Study Finds

Major Review Says New Alzheimer’s Antibodies Offer No Meaningful Benefit

Germany Rules No Added Benefit for New Alzheimer Antibodies After Major Review Finds Little Effect

Blood Test Detects Alzheimer’s Risk Years Before PET Scans

Dual Blood Markers Sharpen Alzheimer’s Diagnosis by Cutting False Positives

Blood Test Using p‑Tau217 Predicts Dementia Risk in Women Up to 25 Years Before Symptoms

Early Alzheimer’s Markers Identified in Peripheral Retina in Mouse Study

Blood ‘Clock’ Predicts Alzheimer’s Symptom Onset Within 3–4 Years

G-BA Finds No Added Benefit for Alzheimer’s Drug Leqembi in Germany

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Never miss stories about

Alzheimer's Disease